Health Care & Hospital Law
Apr. 30, 2011
Biotech Executives Face New Scrutiny from Regulators and Prosecutors
After warning executives they may face sanctions for fraud traced to their companies, federal prosecutors are making good on those threats. A handful of individuals charged offer a glimpse of the new regulatory climate.
Daily Journal Staff Writer
After warning pharmaceutical and medical device executives they may face sanctions for health care fraud traced to their companies, federal prosecutors and regulators are making good on those threats.
A handful of individuals in charge of companies facing hundreds of millions of dollars in civil and criminal fines have been charged with misdemeanors, sentenced for crimes and excluded from federal hea...
For only $95 a month (the price of 2 article purchases)
Receive unlimited article access and full access to our archives,
Daily Appellate Report, award winning columns, and our
Verdicts and Settlements.
Or
$795 for an entire year!
Or access this article for $45
(Purchase provides 7-day access to this article. Printing, posting or downloading is not allowed.)
Already a subscriber?
Sign In